Resource-Adapted Molecular Grouping of Medulloblastoma Using an Extended Immunohistochemical Panel: Correlation with DNA Methylation Profiling
Background Accurate molecular grouping of medulloblastoma is essential for integrated diagnosis and risk stratification but genome-wide DNA methylation profiling remains inaccessible in many resource-constrained settings. Immunohistochemistry (IHC) offers a practical surrogate, but the diagnostic boundaries of conventional panels and the added value of extended marker combinations remain incompletely defined. Methods We retrospectively evaluated 62 medulloblastoma cases from a tertiary neuropathology center. A routine 3-marker IHC panel (β-catenin, GAB1, YAP1) and an extended 7-marker panel (β-catenin, GAB1, YAP1, LEF1, OTX2, Filamin A, p75-NGFR) were compared against DNA methylation profiling as the reference standard in 51 methylation-confirmed cases. MYC/MYCN status was assessed by IHC, FISH and methylation-derived copy-number analysis. Survival analysis was performed using the Kaplan–Meier method. Results Methylation profiling confirmed medulloblastoma in 51/52 cases; one case was reclassified as diffuse paediatric-type high-grade glioma, MYCN subtype. Among 51 methylation-confirmed cases, non-WNT/non-SHH tumors predominated (29/51; 56.9%), followed by SHH-activated (14/51; 27.5%) and WNT-activated (8/51; 15.7%). The routine three-marker panel (β-catenin/GAB1/YAP1) achieved 88.2% concordance (45/51), misclassifying 4 WNT-activated and 2 SHH-activated tumors. The extended seven-marker panel achieved 100% concordance (51/51) in this cohort, correctly assigning all molecular groups. LEF1 outperformed β-catenin for WNT detection (sensitivity 100% vs 50%). A minimal LEF1/GAB1 backbone achieved 98.0% concordance (50/51). MYC amplification was identified in 1/51 cases and MYCN amplification in 2/51 cases; FISH showed complete concordance with methylation-derived copy-number analysis. Conclusion An extended, stringently interpreted IHC panel provides accurate molecular grouping of medulloblastoma and represents a practical, resource-adapted diagnostic strategy where methylation profiling is not routinely feasible.
Authors
- Mariya Varghese
- Ajay Kumar Garg (ORCID: https://orcid.org/0000-0002-9385-291X)
- Chitra Sarkar (ORCID: https://orcid.org/0000-0002-4315-9316)
- Srinidhi Vasant (ORCID: https://orcid.org/0009-0000-0592-5043)
- Vaishali S. Suri (ORCID: https://orcid.org/0000-0001-6485-8194)
- Swati Mahajan (ORCID: https://orcid.org/0000-0002-2287-5866)
- Ashish Suri (ORCID: https://orcid.org/0000-0002-0464-0860)
- Shabnam Mansoori (ORCID: https://orcid.org/0009-0001-7867-7818)
- Kirti Srivastava
- Ashwinee Kumar
- Jyotsna Singh
- Aanchal Verma
Institutions
- All India Institute of Medical Sciences (IN)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1093/noajnl/vdag282
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00